We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Schrodinger, Inc. (SDGR - Free Report) shares rallied 12.1% in the last trading session to close at $23.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.3% gain over the past four weeks.
Schrodinger scored a strong price increase on investors’ optimism surrounding the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management. Tectora focuses on developing therapies for immunology and inflammation. Schrödinger contributed two early-stage small molecule programs and in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform at scale to further advance these programs to clinical candidates.
This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -46.7%. Revenues are expected to be $46.02 million, down 15.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Schrodinger, the consensus EPS estimate for the quarter has been revised 4.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SDGR going forward to see if this recent jump can turn into more strength down the road.
Schrodinger is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, American Well Corporation (AMWL - Free Report) , finished the last trading session 1.4% lower at $13.67. AMWL has returned 12.4% over the past month.
For American Well, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.66. This represents a change of +62.1% from what the company reported a year ago. American Well currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
Schrodinger, Inc. (SDGR - Free Report) shares rallied 12.1% in the last trading session to close at $23.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.3% gain over the past four weeks.
Schrodinger scored a strong price increase on investors’ optimism surrounding the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management. Tectora focuses on developing therapies for immunology and inflammation. Schrödinger contributed two early-stage small molecule programs and in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform at scale to further advance these programs to clinical candidates.
This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -46.7%. Revenues are expected to be $46.02 million, down 15.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Schrodinger, the consensus EPS estimate for the quarter has been revised 4.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SDGR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Schrodinger is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, American Well Corporation (AMWL - Free Report) , finished the last trading session 1.4% lower at $13.67. AMWL has returned 12.4% over the past month.
For American Well, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.66. This represents a change of +62.1% from what the company reported a year ago. American Well currently has a Zacks Rank of #3 (Hold).